Home > Boards > US OTC > Biotechs > Fortress BioTechnology (FBIO)

Avenue Therapeutics Announces First Stage Closing of its

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
conix Member Profile
 
Followed By 166
Posts 25,999
Boards Moderated 10
Alias Born 10/10/05
160x600 placeholder
Avenue Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights GlobeNewswire Inc. - 11/4/2019 7:30:00 AM
Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug Development GlobeNewswire Inc. - 10/28/2019 8:30:05 AM
Avenue Therapeutics to Present Phase 3 Bunionectomy Study of IV Tramadol at the American Society of Anesthesiologists Annual ... GlobeNewswire Inc. - 10/18/2019 8:30:05 AM
Avenue Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights GlobeNewswire Inc. - 8/14/2019 7:30:00 AM
Avenue Therapeutics Announces Appointment of Ms. E. Garrett Ingram to Board of Directors GlobeNewswire Inc. - 8/1/2019 8:00:00 AM
Avenue Therapeutics Announces Positive Topline Data from Second Pivotal Phase 3 Study of Intravenous Tramadol in the Manageme... GlobeNewswire Inc. - 6/3/2019 7:00:00 AM
Avenue Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights GlobeNewswire Inc. - 5/13/2019 7:30:00 AM
Avenue Therapeutics Announces Appointment of Dr. Thomas G. Moore to Board of Directors GlobeNewswire Inc. - 4/30/2019 7:30:00 AM
Market Trends Toward New Normal in Colgate-Palmolive, Nucor, NeoPhotonics, Piper Jaffray Companies, The Ensign Group, and For... GlobeNewswire Inc. - 4/3/2019 8:45:00 AM
Avenue Therapeutics Reports Full Year 2018 Financial Results and Recent Corporate Highlights GlobeNewswire Inc. - 3/12/2019 7:30:00 AM
Avenue Therapeutics Announces First Stage Closing of its Acquisition Agreement with InvaGen (a Cipla subsidiary) GlobeNewswire Inc. - 2/11/2019 7:30:00 AM
Avenue Therapeutics Announces Dosing of First Patient in Second Pivotal Phase 3 Clinical Trial of Intravenous Tramadol for th... GlobeNewswire Inc. - 12/19/2018 8:00:00 AM
B. Riley Financial Enters Agreement to Purchase Fortress Biotech’s Stake in National Holdings GlobeNewswire Inc. - 11/19/2018 8:00:00 AM
B. Riley Financial Enters a Definitive Agreement to Purchase Fortress Biotech’s Stake in National Holdings Corporation GlobeNewswire Inc. - 11/19/2018 8:00:00 AM
conix   Monday, 02/11/19 09:37:41 AM
Re: Awl416 post# 16
Post # of 54 
Avenue Therapeutics Announces First Stage Closing of its Acquisition Agreement with InvaGen (a Cipla subsidiary)

GlobeNewswire•February 11, 2019

NEW YORK, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (ATXI) (“Avenue”), a Fortress Biotech (FBIO) company, today announced the completion of the first stage closing of the Acquisition Agreement previously announced on November 13, 2018 with InvaGen Pharmaceuticals, Inc. (“InvaGen”), a subsidiary of the leading global pharmaceutical company Cipla Limited. The Acquisition Agreement has been approved by a majority of Avenue’s stockholders, including a majority of its non-affiliated stockholders, at its shareholder meeting on February 6, 2019. InvaGen has acquired 5,833,333 shares of Avenue’s common stock at $6.00 per share for total consideration of $35 million, representing a 33.3% stake in Avenue’s capital stock on a fully diluted basis.

About Avenue Therapeutics:

Avenue, a Fortress Biotech company, is a specialty pharmaceutical company focused on the development and commercialization of intravenous (IV) Tramadol for the management of moderate to moderately severe post-operative pain. IV Tramadol may fill a gap in the acute pain market between IV acetaminophen/NSAIDs and IV conventional narcotics. Avenue is currently evaluating IV Tramadol in a pivotal Phase 3 program for the management of post-operative pain. Avenue is headquartered in New York City. For more information, visit www.avenuetx.com.

Avenue Contact:
Jaclyn Jaffe
Avenue Therapeutics, Inc.
(781) 652-4500
ir@avenuetx.com

About Fortress Biotech:

Fortress Biotech is an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential clinical-stage assets. The company has over 25 programs in clinical development at Fortress, at its majority-owned and majority-controlled subsidiaries and at entities it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market therapeutic areas, including oncology, rare diseases and gene therapy, which allow it to create value while mitigating risk for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is driven by a world-class business development team that is focused on leveraging its significant biopharmaceutical industry expertise to further expand the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including Alexion Pharmaceuticals, Inc., City of Hope, Fred Hutchinson Cancer Research Center, InvaGen Pharmaceuticals, Inc. (a subsidiary of Cipla Limited), St. Jude Children’s Research Hospital and UCL Business PLC. For more information, visit www.fortressbiotech.com.

About Cipla Limited:

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology and CNS segments are well-known. Our 44 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Dec’18), 3rd largest in the pharma private market in South Africa (IQVIA YTD Dec’18), and is among the most dispensed generic players in the US. For over eight decades, making a difference to patients has inspired every aspect of Cipla’s work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the movement. A responsible corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its purpose of ‘Caring for Life’ and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on Twitter, Facebook, LinkedIn.

Successful Trading is the art of minimizing long term risk and maximizing capital allocation.
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist